53.40p
-0.74%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Avacta Group
Its shares trade on LSE under the ticker AVCT.L. It has been listed since 8 September 2003. In the fiscal year to 31 December 2024, it reported revenue of £113,000 and a net loss of £52.8m. At that date it held total assets of £48.3m and shareholders' equity of £9.3m.
Avacta Group Plc engages in the provision of Affimer reagents for licensing into third-party research and diagnostic products, and creates new Affimer medicines for development in-house and licensing to large pharmaceutical companies. The company is headquartered in Wetherby, West Yorkshire. The company went IPO on 2003-09-08. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Sept 2003
- Employees
- 119
- Website
- avacta.com/key-information ↗
Leadership
Pay as last reported
- Mr. Shaun ChiltonNon-Executive Independent Chairman of the Board£78,000
- Dr. Christina CoughlinChief Executive Officer, Executive Director, since 2022£551,000
- Mr. Brian HahnChief Financial Officer, Company Secretary
- Dr. Michelle MorrowChief Scientific Officer
- Mr. Simon BennettChief Business Officer - Therapeutics
- Mr. David LiebowitzChief Medical Officer
- Mr. David BryantNon-Executive Director
- Mr. Richard HughesNon-Executive Director
- Ms. Darlene Deptula-HicksNon-Executive Independent Director£96,000
- Mr. Paul FryNon-Executive Independent Director£48,000
- Dr. Mark GoldbergNon-Executive Independent Director£53,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Avacta Group PLC has several strengths that contribute to its overall success and competitive advantage. These include:
Weaknesses
- Avacta Group PLC also faces certain weaknesses, which may hinder its growth and performance. These include:
Opportunities
- Avacta Group PLC has several opportunities that can be leveraged to its advantage in the market. These include:
Threats
- Avacta Group PLC faces certain threats that can negatively impact its business operations and market position. These include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.